Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829192 | 0.99 | FFAR1 (0.35) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829098 | 0.98 | S1PR1 (0.32) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829208 | 0.96 | ALOX5AP (0.33) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL18310565 | 0.95 | FFAR1 (0.32) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829223 | 0.94 | S1PR1 (0.30) | S1PR1S1PR3 | |
| SCHEMBL18310569 | 0.93 | S1PR1 (0.33) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829173 | 0.93 | S1PR1 (0.36) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL18310577 | 0.93 | S1PR1 (0.36) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829206 | 0.92 | S1PR1 (0.35) | FFAR1FFAR4GRM2ALOX5APFEN1 | |
| SCHEMBL19829119 | 0.91 | PTGS2 (0.30) | GRM2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20180030351-A1 | LIQUID CRYSTAL COMPOUND HAVING POLYFLUORO-2-BUTENOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | FFAR1 492/4885FFAR4 1281/4885GRM2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.